Filing Details

Accession Number:
0001127602-16-051285
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-05-05 20:16:28
Reporting Period:
2016-05-03
Filing Date:
2016-05-05
Accepted Time:
2016-05-05 20:16:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1555508 Madhavan Balachandran One Amgen Center Drive
Thousand Oaks CA 91320-1799
Evp, Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-05-04 30,000 $154.12 55,996 No 4 S Indirect By Family Trust
Common Stock Acquisiton 2016-05-03 3,581 $0.00 23,097 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Family Trust
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Nqso (Right to Buy) Acquisiton 2016-05-03 30,490 $0.00 30,490 $156.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,490 2018-05-03 2026-05-03 No 4 A Direct
Footnotes
  1. The price reported is an average price. The prices ranged from $153.53 to $154.54 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
  2. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
  3. These shares include the following RSUs granted under the Company's equity plans: 9,056 RSUs which vest in one installment on 7/31/2016; 2,543 RSUs which vest on 1/28/2017; 3,154 RSUs which vest in one installment of 1,553 on 1/31/2017 and one installment of 1,601 on 1/31/2018; 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019; and 3,581 RSUs which vest in installments of 1,181 on 5/3/2018, 1,182 on 5/3/2019 and 1,218 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  4. These shares include 1,086 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
  5. These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.